MDS
Advertisement
Reactive oxygen species levels decreased and patients with evident bone marrow failure showed hematological response.
A study has explored the clinical impact of both mutation-based and non-mutation-based p53 dysfunction in MDS.
Preclinical models show significant efficacy in combos against AML cell lines with FLT3, KMT2A, NPM1, and TP53 mutations.
Mice treated with the novel approach had a “significantly lower tumor burden” compared with mice that received controls.
The agent recalibrates the immune system to attack tumors and increases cancer susceptibility to standard of care therapy.
Investigational T-Cell Immunotherapy Superior to Standard HSCT in Rate of Survival Plus GvHD Freedom
A phase 3 study comparing the treatments in multiple hematologic malignancies also saw greater overall survival at one year.
Imetelstat is indicated for patients with lower-risk MDS who had an unsatisfactory response to or are ineligible to ESAs.
Detectable MRD before HSCT is associated with worse survival in patients with MDS/MPN compared with undetectable MRD.
Overall survival, nonrelapse mortality, and relapse rates were also assessed in the phase 2 trial which had these results.
The new indication is for use of the alkylating agent with fludarabine in a preparatory combination for allogeneic HSCT.
Juan Jose Rodriguez-Sevilla, MD, PhD, summarizes current clinical knowledge about inflammation within MDS pathobiology.
An MDS HSPC signature generated from the model presents possible targets for treatment in patients with low-risk disease.
The study's results especially highlight potential aberrant gene regulation by ZMAT2 and SMARCD3.
The study showed a mortality risk reduction benefit in certain mutations while for others larger studies are needed.
Researchers noted that confirmation of this relationship in lower-risk disease would require a larger study.
Researchers argue from their findings that the 2023 criteria more accurately present the performance of ivosidenib in MDS.
The combination in a phase II trial produced high complete response rates in patients with newly diagnosed AML.
Researchers also analyzed baseline stem cells for insight into patient response versus non-response to the combination.
The combination was compared with decitabine monotherapy in a multicenter, open-label, RCT.
A study evaluated azacitidine combined with ipilimumab or nivolumab and triplet of these agents in treatment-naive MDS.
Advertisement
630 Madison Ave.
Manalapan, NJ 07726
© 2025 Mashup Media, LLC, a Formedics Property. All Rights Reserved.